Skip to main content
Not Found
Digital Seminar

Realize the Potential of Rapid-Acting Treatments for Depression


Speaker:
Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Duration:
1 Hour 02 Minutes
Format:
Audio and Video
Copyright:
Oct 25, 2024
Product Code:
POS078878
Media Type:
Digital Seminar

Choose a price item
Choose additional price

Description

Optimal management of depression begins with adequate screening and early introduction of appropriate therapy. Monoaminergic antidepressants, which are currently considered the standard of care, have several limitations, including low therapeutic response rates, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence. Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP will explore novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. Discover when newer pharmacologic agents, including neuroactive steroids and glutamatergic antidepressants are appropriate. Take away practical prescriptive considerations and apply them to real-world cases.

Credit

Handouts/Brochure

Speaker

Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP's Profile

Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP Related seminars and products


Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP, practices telepsychiatry on a national scale. With more than a quarter-century of nursing experience, he also holds professorial appointments, academic leadership positions and provides extensive professional consultation services in higher education, industry and clinical affairs. He was associate medical director for the largest managed care behavioral health network in the Desert Southwest and, as a university dean and vice president, he built one of the largest portfolio collections of competency-based graduate nursing degrees in the United States. His professional interests include neurobiology, pharmacology and epigenetics. He is an internationally recognized speaker on these (and related) topics at conferences and professional meetings. He served on the psychiatric medication working group at the Center of Excellence in Regulatory Science & Innovation, an FDA-sponsored project at the University of Maryland. He is a NEI Master Psychopharmacologist and a fellow of the American Association of Nurse Practitioners. The Point of Care Network proclaimed Josh to be America’s Top Psychiatric NP in 2021.


Speaker Disclosures:
Financial: Joshua Hamilton has employment relationships with The Hamilton Group, LLC., Brightside Health, Inc., the University of Nevada, and Washington State University. He is a consultant with Fitzgerald Health Education Associates, Tempus Biotechnology, Wolters Kluwer, Johnson & Johnson Innovative Medicine, and Boehringer-Ingelheim Pharmaceuticals. Joshua Hamilton receives compensation as a consultant and a speaking honorarium from Point of Care Network and Tempus Labs, Inc. He received a speaking honorarium from Myriad Neuroscience, Inc. He receives a speaking honorarium and recording royalties from PESI, Inc. All relevant financial relationships with ineligible organizations have been mitigated.
Non-financial: Joshua Hamilton is a member of National Organization of Nurse Practitioner Faculties, the American Association of Nurse Practitioners, the National League for Nursing, the American Psychiatric Nurses Association, the Neuroscience Education Institute, the Western Regional Advanced Practice Nurses Network, and the American Nurses Association.


Additional Info

Access for Self-Study (Non-Interactive)

Access never expires for this product.

 

For a more detailed outline that includes times or durations of time, if needed, please contact cepepesi.com


Questions?

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info


Objectives

  1. Advance your understanding of the mechanisms of action for novel rapid-acting pharmacotherapies for depression.
  2. Evaluate the efficacy and unique safety profiles associated with novel antidepressants.
  3. Select appropriate patients for treatment with rapid-acting antidepressants.
  4. Explain the skills needed to engage in shared decision making to optimize patient outcomes.

Outline

Novel Rapid-Acting Pharmacotherapies for Depression: Mechanisms of Action
  • Treatment-as-usual
  • Unmet needs
  • MDA receptor antagonists
  • Neuroactive steroid GABA-A modulators
Efficacy and Unique Safety Profiles Associated with Novel Antidepressants
  • Neurobiology of depression, revisited (GABA/glutamate)
  • Clinical studies and outcomes
Select Appropriate Patients for Treatment with Rapid-Acting Antidepressants
  • Case applications
  • TRD/anhedonia
  • PPD
  • Suicidality
Shared Decision Making to Optimize Patient Outcomes
  • Shared decision-making with patients
  • Case applications, continued

Target Audience

  • Nurse Practitioners
  • Nurses
  • Physician Assistants
  • Physicians
  • Pharmacists

Reviews

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or call 1-800-844-8260.

ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.

PESI Mobile App

Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of online courses from the world’s best instructors, and complete your CE requirements anywhere, anytime, at your own pace.

https://cdn.pesi23.com/images/android.png     https://cdn.pesi23.com/images/iphone.png

Please wait ...

Back to Top